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First Description and Search for as ’a bacillary infectious disease, which is either
Aetiology identical with tuberculosis or closely related to
it’, however, proof of this hypothesis remains
A number of the characteristics of the disease elusive. Nevertheless, there is an ongoing discus-
known today as sarcoidosis were first described sion of this question. Using methods of histology
in the 18th and 19th centuries. In 1798 erythema and molecular biology the presence of acid fast
nodosum was described by William, and as early rods, mycobacterial DNA and mycobacterial rRNA
as in 1882 the microscopical characteristics of has been demonstrated in sarcoidosis.4-6
epitheloid and giant cells were reported by Ten- However, other investigators have not been able
neson. In 1889 Ernest Besnier, a French derma- to reproduce these findings and, based on the
tologist, presented a 34-year-old man with lesions assumption that per 10 host cells of established
on the face and upper limbs. He considered the lesions more than 15 organisms are required to
facial changes related to lupus erythematodus, an play a pathogenetic role, it has been concluded
autoimmune disorder characterized by facial skin that Mycobacterium tuberculosis, other myco-
lesions. The term ’lupus pernio’ shaped by bacteria, or closely related organisms are not
Besnier is still used today to describe facial skin involved in sarcoidosis,
7-1 recently reviewed by
lesions of sarcoidosis patients. Mangiapan and Hance.
1
Sarcoidosis is regarded today as a systemic dis- In addition, a number of other infectious
order which can affect virtually all organs of the organisms have been claimed to be capable of
body. This view is based on the work of Kuz- inducing sarcoidosis. For example, mycolasma-
nitzky, Bittorf and Schaumann. In 1914, J6rgen like organisms
12 or Borrelia burgdorferi
3 have
Schaumann, a Swedish dermatologist, wrote a recently been proposed as a possible cause of
prize-winning essay on lupus pernio, in which he sarcoidosis, however, for the latter, data obtained
expressed the view that Besnier’s lupus pernio by our group do not support this hypothesis.
14
and Boeck’s multiple sarcoids are manifestations Epidemiological data and similarities with
of the same disease, that this disease might also other infectious diseases support the hypothesis
involve the lymph nodes, the mucosa of the that sarcoidosis is induced by an infectious agent.
nose, the tonsils, the bones and the lungs, and Seasonal clustering of sarcoidosis in the months
that all of these manifestations are characterized of June and July,
.5 time. and space clusters,16’17
by a histological pattern which he summarized as an increased incidence in health workers,
18 and
a ’tuberculoid granulomatous process’. Schau- the transmission of sarcoidosis by transplants
9
mann suggested the term ’lymphogranulomatosis have been observed and further support the
benigna’ for the disease since it appears to hypothesis of transmissible agents inducing sar-
involve predominantly the lymphatic system. In coidosis. Most interestingly, there are numerous
this essay published in 1934 he identified radio- reports of sarcoidosis patients who suffered from
graphic changes of the bone due to sarcoidosis a relapse of sarcoidosis in a transplanted lun2 and typical histological changes in different despite receiving immunosuppressive therapy.
organs, thus demonstrating that an affection of Vice versa a patient receiving a lung from a
the skin is not mandatory for the diagnosis of donor who had a spontaneous remission of sar-
sarcoidosis.2’ coidosis in the past was observed to develop
As early as 1905 Boeck described sarcoidosis sarcoid-like lesions. These observations suggest
(C) 1996 Rapid Science Publishers Mediators of Inflammation Vol 5 1996 241J. M2"ller-Quernheim
that the aetiological agent hides within the lung loosely arranged cells like a collar of lympho-
and/or in other compartments of the body. cytes, monocytes, and fibroblasts (Fig. 1).22,25
Despite the efforts made to elucidate the aetiol- Although many microscopic features may suggest
ogy the statement made by Longcope and Frei- sarcoidosis, the epitheloid granulomas, especially
mann in 1952 is still true: ’The aetiology of in their earlier stages, are indistinguishable from
sarcoidosis is still obscure, the relation which it those of other idiopathic granulomatous dis-
bears to tuberculosis or possibly other forms of orders.
granulomata remains a matter of contention and Thus, sarcoidosis is best defined in histopatho-
the conclusive demonstration of its presence logical terms as ’a disease characterized by the
rests entirely upon the histological structure of presence in all of several affected organs and
the lesions which it produces The most tissues of non-caseating epitheloid-cell granulo-
telling contribution that could be made to our mas, proceeding either to resolution or to con-
knowledge of this peculiar condition would be version into hyaline connective tissue’.
22 The
the discovery of its aetiology.
’2 clinical diagnosis, however, can only be sup-
ported by typical histopathological findings.
Pathognomonic criteria or a diagnostic ’golden
standard’ are absent. Definition, Natural Course of the Disease,
and Treatment Most patients with diagnosed sarcoidosis will
undergo clinical and radiological resolution of
An evaluation of transbronchial or open lung the disease over a period ranging from several
biopsies of patients in the early stage of disease months to a few years.
26 A few of them develop
supports the clinical diagnosis by demonstrating a progressive form of the disease which may
the typical findings of noncaseating granulomas result in death.
27 Only rough estimates of the
within the alveolar, bronchial and vascular mortality of untreated sarcoidosis are available. If
walls.22-24 These granulomas are diffusely scat- untreated a mortality of about 5% is estimated.
tered throughout the lung parenchyma. They are The aetiology of sarcoidosis remains unknown
usually of varying age, ranging from highly cel- and, therefore, no specific treatment is possible.
lular lesions to collections with diminishing cellu- Fortunately, many patients will not require treat-
larity, some fibrosis, and progressive ment because the symptoms are not disabling
hyalinization. Two characteristic zones can be and frequently remit spontaneously. Prompt
seen in a typical, well-developed sarcoid granu- initiation of corticosteroid therapy, however, is
loma: (i) a central zone or follicle which is tightly indicated when granulomas cause dysfunction in
packed with cells, composed primarily of macro- vital organs or when the inflammation is particu-
phages, multinucleated giant cells, and epitheloid larly disabling or when disfiguring skin lesions
26 cells; and (ii) a peripheral zone containing emerge.
FIG. 1. Light photomicrograph of a typical non-caseating granuloma with multinucleated giant cells.
25
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Bronchoalveolar Lavage
Although the technique of bronchoalveolar
lavage (BAL) was introduced in the 1920s,
28 the
first article describing pulmonary alveolar lavage
as a method for harvesting large numbers of
macrophages from the rabbit lung was not pub-
lished until 1961 by Myrvik et al.29 Finley et aL3
have demonstrated that BAL can be safely per-
formed in humans using a wedged catheter. With
the introduction of the fibre-optic bronchoscope
into clinical medicine by Ikeda et aL1 BAL has
become widely used for clinical investiga-
tions.32’33 The observation of characteristic
changes in the cytology of BAL in interstitial lung
diseases first reported by Hunninghake in 1971
gave rise to a large number of detailed investiga-
tions of pulmonary immunology in health and
disease.4 The findings obtained by various
researchers over the past 15 years form the basis
of a concept of the immunopathogenesis of sar-
coidosis discussed in the following.
Ultrastructural Changes
In addition to granulomas, the morphological
appearance of sarcoid of the lung has many of
the features typical of mild interstitial lung dis-
eases. Early in the disease unspecific ultra-
structural lesions of the air-blood barrier can be
observed, frequently even in areas of the lung
which appear normal using light microscopy. The
alveolar walls are expanded. The type epithelial
cells of the alveoli are injured denuding the basal
membrane of a number of alveoli. These defects
are covered by cuboidal cells, primarily pneumo-
cytes type II. In other areas, the endothelial cells
are damaged and capillaries are replaced by con-
nective tissue. In rare cases a fibroblast prolifera-
tion in the alveolar and/or bronchial walls can be
observed; it is these cases in which various
amounts of dense fibrosis are observed replacing
the normal parenchymal structures,
5 thus hin-
dering the gas exchange.
Similar lesions can be observed in various din-
ical or experimental conditions including asbes-
tosis, idiopathic pulmonary fibrosis,6’37
pulmonary histiocytosis X,
38 systemic sclerosis
with lung involvement,39 early stages of ARDS,
4
X-ray irradiation, paraquat, bleomycin, or 3-
41 42 methylindole toxicity, and exposure to nitro-
gen or oxygen.
4 The occurrence of similar reac-
tions in such different conditions supports the
concept of a common pattern of pulmonary
response to diverse injuries.
A sequela of the early damage to the morphol-
ogy of the basal membrane in interstitial lung
diseases is a change in the composition of the
alveolar lining fluid. Albumin and glucose are
found at high concentrations in the alveolar
lining fluid of patients with sarcoidosis4 which
may be due to leakage in the basal membrane or
to a defect of the epithelial cells resulting in a
decreased transmembrane transportation rate
from the alveolar lumen back to the interstitium.
These changes correlate with various parameters
of inflammation, e.g. cellularity of BAL. In addi-
tion, dramatic changes in the composition of the
surfactant are observed in interstitial lung dis-
eases, indicating an alteration in type II epithelial
cells which produce the surfactant proteins and
phospholipids.44’45 These proteins are now
recognized to exhibit immunomodulatory func-
tions, either anti- or pro-inflammatory in
nature.44’46’47 The pathophysiological role of the
interaction of epithelial lining fluid components
and cells of the lower respiratory tract are
unknown and represent a new and exciting field
of research.
Alveolar Macrophages
Alveolar macrophage activation in sarcoidosis:
Due to a considerable increase in lavage cellular-
ity, the absolute number of alveolar macrophages
expands in sarcoidosis while the relative number
decreases. The percentage of alveolar macro-
phages with monocytic appearance is elevated in
sarcoidosis, suggesting a recent immigration of
monocytic precursors of alveolar macrophages
from the blood.48-5 A number of cytokines che-
motactic for monocytes, e.g. interleukin-1 (IL-1),
tumour necrosis factor z (TNFez), macrophage
inflammatory protein-lz (MIP-Iz), and colony
stimulating factors, are produced by alveolar cells
in the course of inflammatory reactions of sar-
coidosis and other interstitial lung diseases,
5-55
supporting the notion of monocyte immigration.
However, those markers characteristic of a
monocytic immunophenotype can be acquired
by alveolar macrophages in the course of activa-
tion.5 Thus, the question of monocyte immigra-
tion is not yet settled.
The activated state of these cells has been
demonstrated on the basis of their spontaneous
in vitro production of IL-1.56 Results of the first
report could not be reproduced by other investi-
gators, although IL-I-mRNA was found in these
cells.57 A number of researchers have subse-
quently repeated these experiments and observed
IL-1 in the supernatants of alveolar macrophages
58 6O of patients with active sarcoidosis. In addi-
tion, IL-1 inhibitors and IL-1 receptor antagonist
were identified in BAL fluid and cell culture
supernatants, thus providing at least a partial
explanation of the conflicting results.61’62
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Since the publication of the above results a
number of monokines, i.e. TNFz, IL-6, MIP-10t,
and monocyte chemotactic protein-i, have been
identified as being released by alveolar macro-
phages in the course of sarcoidosis.52’58-6’63’64
Analysing the release of TNF0t and IL-6 by these
cells revealed that the activation of the cells of
the monocyte/macrophage lineage is compart-
mentalized, i.e. alveolar macrophages release
these mediators spontaneously, whereas the cor-
responding cells of the peripheral blood are
quiescent (Table 1).6’63 In sarcoidosis TNFcz is
released at high concentrations at the place of
the inflammatory reaction, however, a corre-
sponding cachectin effect is absent in most
patients, giving rise to the hypothesis that TNFz-
binding or-neutralizing proteins or counter-
acting cytokines are simultaneously released. The
fact that IL-6 proved in in vitro experiments to
be capable of down-regulating the release of
other pro-inflammatory cytokines, such as TNFz
and IL-1,65 led to the hypothesis that in vivo IL-6
might be able of dampening the alveolitis of sar-
coidosis or even of inducing a spontaneous
regression of the disease. However, the coex-
pression of TNF0t and IL-6 in active sarcoidosis
and the absence of IL-6 release of BAL cells from
patients with inactive disease demonstrate (Table
1) that IL-6 does not exert detectable anti-inflam-
matory actions in sarcoidosis. Furthermore,
soluble TNF-receptors (sTNF-R) may well be
capable of counteracting TNFz effects.66 Pre-
liminary results obtained by our group demon-
strate the presence of increased sTNF-R serum
levels correlating with alveolar macrophage TNFez
release and might, therefore, play a role in damp-
ening the cachectin effects of TNFz (Fitschen,
unpublished results). However, increased levels
of both forms of the sTNF-R can be found in the
alveolar lining fluid of patients with sarcoidosis
and numerous interstitial and obstructive lung
diseases55 making it unlikely that they play a spe-
cific role in the immunopathogenesis of sarcoid-
osis.
Kinetic studies on the transcriptional level of
the TNFz-gene revealed that maximal mRNA
transcription is reached within 2 h after stimula-
tion. Cytoplasmic TNFz was detected as early as
1 h after stimulation, culminating during the next
2 h to be followed by a decline.7 Similar experi-
ments with sarcoid alveolar macrophages
revealed the transcription of the TNFz-gene at
the time of BAL and its down-regulation during
the next 24 h in cell culture.6 Thus, the height-
ened spontaneous TNFez release seen in active
sarcoidosis is the consequence of an in vivo acti-
vation step just prior to the removal of the cells
from the lung indicating that the eliciting agent
resides in the lower respiratory tract. In parallel
to the findings on the transcriptional level the
highest amount of TNFz is released during the
first 3 h of in vitro culture followed by a sharp
decline,s Therefore, it can be concluded that
TNFz release is regulated in a physiological
manner in those cells and that the putative agent
causing sarcoidosis does not interfere with the
regulation of the TNFcz release neither on the
transcriptional nor on the post-transcriptional
level.
Subsequent cytokine studies were extended to
Table 1. Spontaneous release of TNF and IL-6 by cells from patients with active or inactive pulmonary sarcoidosis*
Cells Spontaneous release of IL-6
(pg/ml/106 cells, median,
range)
Spontaneous release of TNF
(pg/ml/106 cells, median,
range)
Alveolar macrophages active sarcoidosis
Alveolar macrophages inactive sarcoidosis
Alveolar macrophages controls**
Peripheral blood mononuclear cells active sarcoidosis
Peripheral blood mononuclear cells inactive sarcoidosis
Peripheral blood mononuclear cells controls
012 156
104-3 264 100-17 352
(n 16) (n 46)
112 388
0-977 0-1 643
(n 12) (n 27)
141 291
0-604 0-1 011
(n= 12) (n=26)
144 377
0-312 0-4 122
(n 22) (n 41)
77 476
0-153 0-943
(n 19) (n 24)
91 306
0-124 0-887
(n =16) (n 23)
26 Inflammatory activity of disease was judged on the basis of clinical symptoms and organ dysfunction, data from Refs 60 and 63, supplemented with
unpublished data.
Patients undergoing diagnostic bronchoscopy being retrospectively free of any inflammatory or malignant lung disease served as controls.
2.44 Mediators of Inflammation Vol 5 1996Sarcoidosis
include the interstitium and the lymph node
showing a simultaneous activation of alveolar
macrophages, interstitial macrophages, and mac-
rophages in the granulomas.
8 In general, inter-
stitial macrophages differ from alveolar
macrophages in the relative expression of immu-
nological functions. The latter are poor accessory
cells and IL-1 producers, but appear to be better
equipped to clear infectious agents from the
lower respiratory tract, whereas interstitial macro-
phages have higher accessory and immuno-
regulatory capabilities.5v’9-v In marked contrast,
the accessory capabilities of sarcoid alveolar mac-
rophages have been found to be increased as
measured in mixed lymphocyte reactions and
antigen presentation.7’74 However, the inter-
pretation of these experiments has been compli-
cated by possible stimulations via minor
histocompatibility antigens or by intrinsic activ-
ities of autologous sarcoid T-cells present in the
test. In a different cell culture system using a
method insensitive to histo-incompatibilities,
sarcoid alveolar macrophages were shown to
express increased accessory functions mediated
by adhesion molecules, e.g. CD80]5
Down-regulation of alveolar macrophage activ-
ity.. The characteristics of the stimulated alveolar
macrophages described above suggest an activa-
tion in the course of a normal immune
response. In approximately 60% of all sarcoid
patients spontaneous regression of the disease is
observed. Therefore, down-regulating mechan-
isms inducing spontaneous remission should be
present in sarcoidosis.
Transforming growth factor-[ (TGFI) is a
member of the superfamily of ubiquitous reg-
ulatory proteins which are necessary for cell
growth, cell differentiation, and regulation of
extracellular matrix production. Growing evi-
dence also confirms its role as an immunomodu-
lator, exhibiting pro-inflammatory and anti-
inflammatory properties.7-79 Interleukin-10 is
another potent inhibitor of monocyte/macro-
phage- and T-cell-activation. It inhibits the cyto-
kine production and proliferation of human
80 82 monocytes and T cells and the TNFa release
of human+pulmonary dendritic cells.8 CD4 + Th0
and CD4 Th2 cells are the major IL-10 produ-
cing cells84’85 while macrophages and monocytes
also release IL-108’8 although to a lesser extent.
IL-10 is capable of suppressing the release of
TNFa and IL-1 by LPS activated alveolar macro-
phages in a dose-dependent manner. IL-6 release,
however, is not affected by IL-10 (Fig. 2). TNFa
and IL-1 are two key-mediators in sarcoid alveoli-
tis required for the induction and maintenance of
8 granulomata. Thus, IL-10 is a candidate cytokine
120
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FIG. 2. Effects of IL-IO on cytokine release by stimulated alveolar
macrophages (n 10). Cells were stimulated with lg LPS per
ml in the presence of recombinant human (rh)lL-lO. Controls
were stimulated with LPS without rhlL-10. TNF=, IL-I, and IL-6
concentrations were measured in the cell culture supernatants
and expressed as a percentage of the LPS-stimulated control
culture. The reductions of TNF= and IL-I release are significant
(p < 0.001 in all comparisons). IL-6 release was not influenced
by the presence of IL-IO (p > 0.2). Taken from Zissel eta/.99
for the induction of the spontaneous regression
of sarcoidosis. Due to its TNFa suppressing cap-
abilities high levels of IL-10 are anticipated in
patients with low TNFt release and vice versa.
As expected, in cell culture supernatants of
alveolar macrophages of sarcoid patients contain-
ing high concentrations of TNFa counteracting
IL-10 could not be found. In those supernatants
with low concentrations of TNFa, however, in
which an anti-inflammatory action has to be
assumed IL-10 was absent indicating that the
mechanism controlling the alveolitis does not
employ this mediator.
88
In an experimental protocol as described
above for IL-10 a suppressive effect of TGF[3 on
LPS-activated, human alveolar macrophage cyto-
kine release could not be detected. Employing
lower concentrations of LPS, however, disclosed
a dose-dependent suppressive effect of TGF[3 on
this type of cells. 100 ng/ml or 10 ng/ml of LPS
are to potent stimulatory signals to be counter-
acted by TGF[. Stimulation by 1 ng LPS/ml or in
vivo stimulations resulting in an in vitro TNFa
release result in an activation which can be
down-regulated by TGF[. By the presence of
200-1 000 pg TGF[ per ml the TNFa release of
cells stimulated in such a way was significantly
reduced to 65-89% of control cultures without
TGF[ (Fig. 3).
In the lung the inactive form of TGF[ is an
89 9O abundant cytokine and mechanisms activating
TGF[ can be observed during alveolitis. The
release of proteases
9 and the acidification of the
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therapy (Group I: 677 +_ 159 pg/ml) or had evi-
dence of persisting disease when no therapy was
administered (Group III: 762 419 pg/ml). In
marked contrast, eight out of twelve patients with
active disease who had a spontaneous remission
of disease within the following six months
(Group II: 1 422 215 pg/ml) exhibited ele-
vated TGFI3 release by BAL cells. In these
patients TGFI3 release differed significantly from
e00r that recorded in Groups I, III and controls (II
1000 pg TGFI versus III: p < 0.04, II versus I and II versus
control: p < 0.004). Most interestingly, in 5/5
00 patients under therapy elevated TGFI3 release was
ps{,/rl also observed (Group IV, 1 698 -t- 244 pg/ml)
and differed significantly from Groups I, III and
FIG. 3. Inhibition of TNF0 release by alveolar macrophages (n controls (p < 0.04 for all comparisons, Fig. 4).
10) stimulated by various LeS doses. Cells either without in vitro Groups I (requiring therapy) and II (sponta-
stimulation or stimulated with 1, 10, or 1OO ng LPS per ml were
incubated with 200 or 1000 pg TGFI per ml. TNF0t in cell neous remission) exhibited a markedly elevated
culture supernatants was estimated by an ELISA and expressed TNFcz release by BAL cells (1 952 +_ 856 pg/mi
as a percentage of control without TGFI. The TNF0 release sup- and 2 374 + 971 pg/ml, respectively) which
pressed by TGFI3 at O ng LPS was stimulated in vivo by the
disease of the respective patients (*p < 0.05). Taken from Zissel proved to be significant in comparison with con-
eta/.99 trois (p < 0.02 for both comparisons). The two
other groups, persistent disease (Group III) and
receiving therapy (Group IV) did not exhibit ele-
vated TNF0 release (326 98 pg/ml and 123 _
micromilieu92 by these cells are mechanisms 52 pg/ml, respectively, Fig. 4).
known to activate TGF139 and known to be In addition, IL-2 concentrations were estimated
present in sarcoid alveolitis.7]’9’93-96 In addition, in BAL cell culture supernatants of the four study
cells of the monocytic type as can be found in groups. In Group I (requiring therapy) and in
sarcoid alveolitis48’9 release preactivated TGF
98 Group II (spontaneous remission) elevated IL-2
and activated alveolar macrophages have been .levels (9.8 -t- 4.5 U/ml (n 12)and 2 4- 1.4
shown to down-regulate pro-inflammatory cyto- U/ml (n 5) respectively) without statistically
kine release in response to TGFI].
99 This leads to significant differences were observed. In Group
the hypothesis that this cytokine might be III (persistent disease)3/3 patients had undetect-
involved in the down-regulation of sarcoid able IL-2 levels. In Group IV (receiving cortico-
inflammation which was tested in a clinical study, steroids), however, 1/3 patients showed an ele-
For this purpose sarcoid patients were categor- vated IL-2 release (Fig. 4).
ized into four groups: Group I consisted of Although" pro-inflammatory cytokines. 87 are. con-
patients with active disease exhibiting new or sidered to maintain sarcoid alveolins their pres-
progressing symptoms. At the time of broncho- ence is not associated with a state of disease
scopy indications for therapy were given and the requiring therapy if their action is counteracted
patients received corticosteroids after broncho- by an anti-inflammatory mediator such as TGFI3,
scopy. Group II also exhibited signs of active as can be seen from the difference in the course
disease at the time of clinical examination, of the disease between Groups I and II in the
however, due to the absence of indications no above-described study.
88
therapy was administered. After 6 months the Considering the known immunomodulatory
supernatants of these twelve patients were allo- effects of TGF[3 a direct anti-inflammatory action
cated to Group II because spontaneous remis- in sarcoid alveolitis seems conceivable. It can
sion had occurred within the 6 months following function as an autoregulatory lymphokine that
the investigation. Patients with persisting signs of limits lymphocyte expansion as it has been
active disease, who did not receive therapy and demonstrated for T-cells. After mitogen stimula-
showed no spontaneous remission were allo- tion T-cells express the genes for pro-inflamma-
cared to Group III. The patients in Group IV tory cytokines as well as for TGFI3 and
received either corticosteroid therapy or pred- accumulate TGFI3 protein. However, its release is
nisolone plus azathioprine at the time of delayed consistent with a auto-regulatory role in
100 101 bronchoscopy, limiting T-cell expansion so that it can
Sarcoid patients whose BAL cells released low dampen the IL-1- and IL-2-responses of T-cells
amounts of TGF[3 either required corticosteroid and therefore limit the inflammatory reac-
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FIG. 4. Release of TGFI (upper panel), TNFz and IL-2 (lower
panel) by the four groups of sarcoid patients. Cytokines were
measured in supernatants of cultured BAL cells (106 cells/ml,
24h) either by bioassay (TGFI and IL-2) or by ELISA (TNF).
Mean of TGFI release is significantly elevated in Group II (spon-
taneous remission) and in Group IV (patients under therapy)indi-
cated by bold lines. In Group (requiring therapy) and Group III
(persisting disease) TGFI release is below the upper limit of the
normal range. TNF and IL-2 release is elevated in Group and II
whereas it is within the normal range in Groups III and IV. Upper
limits of TGFI, TNF and IL-2 release derived from seven (TGF),
14 (TNFz) and 13 (IL-2) controls are indicated by the arrows
(TNFz left, IL-2 right side). Taken from Zissel eta/.88
tion.76’2-4 This concept is further supported
by findings in TGF[ knock-out mice. In these
mice an excessive accumulation of inflammatory
cells in several organs, including the lung, can be
obseed. In most animals death can be attrib-
uted to the effects of leukocyte infiltration in vital
organs leading to the concept that TGF[ is
required to counteract T-lymphocyte activation
and expansion.5’6 In pulmonary sarcoidosis
this TGFI effect seems to be involved in the
induction of spontaneous regression of the
disease. Owing to the multiple TGFI activating
mechanisms in the micro-milieu of inflamed
organs and the different status of receptor
expression of the target cells it is extremely diffi-
cult to identify the role of TGFI in a given
immunopathological situation, discussed by
Wahl.7
Macrophages can be deactivated by TGFI and
its mode of action is well described. In contrast
to IL-10, which promotes degradation of pro-
inflammatory cytokine mRNA, TGF[ inhibits
post-transcriptional mechanisms in TNFz, IL-Iz,
and IL-113 production. It does not affect the level
of TNFz mRNA, the release of preformed TNFz
nor the degradation of TNFz. Thus, TGF appears to inhibit translation of TNFz mRNA.7’9
In general, TGFI enhances monocytic function
which is mediated by TGF-receptors expressed
in high density by these cells,m8 During the
process of maturation to macrophages the recep-
tor expression is down-regulated and the ligand
binding to the remaining receptors induces deac-
tivating mechanisms8’m9 making it feasible that
the above described in vitro mechanisms act in
vivo.
The patients in Group II of the study de-
scribed above have a good prognosis and are cer-
tainly not under the risk of developing
pulmonary fibrosis. High concentrations of TGFI
can, however, be observed in a number of in
vivo and experimental situations resulting in
fibrosis. Increased collagen synthesis in an animal
model of hypersensitivity pneumonitis is asso-
ciated with heightened TGF[ levels and can be
abrogated by anti-TGF[ antiserum.m In bleomy-
cin-treated mice, a model of pulmonary fibrosis,
blocking of TGFI by antibodies prevents fibrosis
as well.;11’12 The foregoing data suggest that an
increase in TGF[ concentration leads to fibrosis.
Supporting this concept in chronic liver
disease,’4 systemic sclerosis,
5 pulmonary
fibrosis114’116 and a number of other disorders
with tissue fibrosis117 such an increase of TGF
has been identified. However, the response of
fibroblasts to TGF# differs with the state of
disease and their expression of receptors for
other cytoldnes like platelet-dedved growth
factor. Fibroblasts of different organs differ in
their response to TGFI, e.g. lung fibroblasts
down-regulate and scleroderma skin fibroblasts
up-regulate their platelet-dedved growth factor-
receptors whereas normal skin fibroblasts do not
modulate this receptor in response to TGF.
118
These findings are compatible with the concept
that TGF[, hence activated,
9 uses its anti-inflam-
matory capabilities demonstrated for macro-
100 99 119 phages, T- and B-lymphocytes,
,20,121 cell
122 proliferation, and cytokine release12 to down-
regulate pulmonary inflammation.
A study with inbred mice demonstrated that
the susceptibility to the induction of pulmonary
fibrosis by bleomycin sulphate is strain depen-
dent. The lungs of bleomycin treated fibrosis
susceptible C57BL/6J and fibrosis resistant BALB/
cBy mice were analysed for their mRNA expres-
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sion level of a panel of cytokines. TGF]3 mRNA by T-cells.35 Furthermore, IL-4 and interferon-7
was found to increase seven-fold after bleomycin (IFN7), both products of activated T-cells, have
treatment in sensitive and three-fold in resistant been confirmed to decrease CD14 expression on
animals. Analysis of F1 hybrids, which were monocytes/macrophages by decreasing transcrip-
shown in this report to be sensitive to bleomy- tion of the CD14 gene. It has been demon-
cin-induced fibrosis, revealed a segregation of a strated that IFN7 is released spontaneously by T-
cytokine pattern completely concordant with the lymphocytes of patients with active sarcoidosis6
segregation of susceptibility phenotypes between and that elevated levels of circulating IFN7 in
the parental and F1 strains, i.e. the expression of serum can be detected in most untreated
IL-6 and TGF[3. This result indicates a possible patients with sarcoidosis.3
association between sensitivity to bleomycin- In this context changes in CD14 expression by
induced fibrosis and inducibility of IL-6.124 In this macrophages/monocytes and an increase in
context it can be concluded that for the induc- sCD14 may be expected in sarcoidosis patients.
tion of fibrosis besides the presence of activated Sarcoid alveolar macrophages were found to
TGF]3 a number of other immunobiological pre- express exaggerated levels of surface CD145’138
requisites, such as IL-6 expression, need to be and in the alveolar lining fluid its soluble form is
fulfilled and it seems feasible that the association increased in active sarcoidosis.39’14 Interestingly,
of TGF3 expression and good prognosis of a small increase in sCD14 serum levels correlat-
sarcoid alveolitis is a crucial immunoregulatory ing with neopterin and angiotensin converting
phenomenon of this disorder. The notion of a enzyme was observed. Unfortunately, the
potent anti-inflammatory action of TGF[3 is changes in sCD14 serum concentration induced
further supported by the finding that highly by sarcoid immunopathological mechanisms in
immunogenic murine tumours transfected with vivo are of a magnitude which prevents the
TGF]3 cDNA escape immunosurveillance.25 exploitation of this phenomenon for clinical pur-
poses.
4
Clinicalparametersfor the evaluation of macro- Neopterin, a small, 250 Da metabolite of the
phage activity: Parameters suitable to gauge the guanosinetriphosphate pathway is released by
activity of the cells of the macrophage/monocyte activated macrophages and monocytes under the
lineage in sarcoidosis have been delineated, control of IFN7 produEed by T-cells.14 As
Lysozym and angiotensin converting enzyme are expected, elevated serum levels were found in
products of epitheloid cells creating elevated sarcoidosis and are used to monitor the activity
serum levels in sarcoidosis. These serum levels of cells of the macrophage/monocyte lineage in
40 142 143 reflect the granuloma burden of the entire body the course of the disease. Interestingly, a
and can be used for a clinical assessment of the correlation between BAL cell TNFa or IL-6
granulomatous inflammation.126’127 These serum release with serum neopterin could not be
parameters are frequently used in everyday prac- observed6 giving rise to the hypothesis that the
tice and their rise indicates an ongoing inflamma- elevated neopterin levels are sequelae of cell acti-
tion with an increasing number of vations in other body-compartments than the
granulomas.
26-28 The angiotensin converting alveolar space, such as lymph nodes providing
enzyme concentration in alveolar lining fluid cor- secreted molecules an easy access to the serum.
relates with that of the serum and a number of Nevertheless, serum or urine neopterin con-
parameters describing pulmonary inflammation, centration proved to be a very useful clinical
e.g. percentage of BAL lymphocytes.29 However, parameter to probe the activity of the cells of the
this parameter is not specific and it can be found monocyte/macrophage lineage in the course of
140142--144-- elevated in a number of interstitial lung dis- sarcoidosis.
eases.29’3 It has to be kept in mind that none of the
CD14 is the most specific marker for cells of above-mentioned parameters can be used to
the monocyte/macrophage lineage-
and its establish a diagnosis. Elevated levels are found in
expression is age, race and gender indepen- a number of diseases. Once the diagnosis of sar-
dent.4 Reports concerning expression of CD14 coidosis has been made, the inflammatory activity
on alveolar macrophages in healthy volunteers .of the immunopathogenetical processes de-
and in sarcoidosis patients are controversial, scribed above can be monitored by the use of
however, its soluble form (sCD14) could serve as these serum parameters.
an ideal serum parameter to monitor the con-
tribution of these cells to sarcoid inflammation. It T-cells has been shown in in vitro experiments that the
expression of CD14 by pokeweed mitogen acti- T-cell activation: Sarcoidosis is associated with
vated monocytes/macrophages is down-regulated an increase in the number of alveolar T-cells, and
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a shift to an increase in CD4 + cells within these
cells can be observed. In normal BAL up to 20%
T-cells with a CD4/CD8 ratio ranging from 1.0 to
3.0 (median 2.2)45 may be found. Apart from a
small number of neutrophils (< 5%) the
remaining cells are alveolar macrophages. In
some cases of sarcoidosis more than 50% T-cells
with a CD4/CD8 ratio > 10 can be observed
exhibiting markers of activation, such as
increased HLA-DR, VLA-1, and interleukin (IL)-2
receptor expression and capping of the T-cell-
antigen receptor.4’46-15
Without any stimulation in tissue culture these
T-cells have been found to release in vitro IL-2.
This finding represents the first demonstration of
the involvement of IL-2 in the immunopathophy-
siology of a human disease.51’152 In spite of the
systemic nature of the disease only the alveolar
T-cells--but not those of the peripheral blood--
secrete IL-2.5 Interestingly, the regulation of the
transcription of the IL-2 gene appears to be
normal indicating a stimulation of the cells in a
physiological fashion.15 This view is supported
by the finding of duBois et aL who demonstrated
a capping of the T-cell-antigen receptor of alveo-
lar T-cells in sarcoidosis suggesting a recent acti-
149 vation of the cells via this complex. These two
phenomena can be observed in cells of the BAL,
indicating that the eliciting agent resides in the
lung or that activated cells are attracted to the
lung as observed in animal models of pulmonary
inflammation. 154
Owing to the fact that the genes of IL-2 and IL-
2R are coexpressed the enumeration of IL-2R posi-
tive T-cells was considered to be an approach to
estimate the number of activated alveolar T-cells.
Only a moderate increase in IL-2R+ T-cells was
observed,148’55’156 suggesting the presence of a
small number of activated cells in the alveolar
space or a dysregulation in the expression of the
IL-2R. Results obtained by an in vitro study with
sarcoid T-cells excluded the latter possibility.
48
Other immunological disorders, e.g. rheumatoid
arthritis and multi_pie sclerosis, also exhibit small
increases in IL-2R--T-cells at the site of inflamma-
tion, i.e. the synovial surface and the multiple
sclerosis lesions, respectively, thus supporting the
157 158 above-mentioned finding. However, the
milieu of the lower respiratory tract generated by
pulmonary epithelial cells type II modulates the
reactivity of the T-cells. In the presence of type II
epithelial cells activated T-cells become arrested
and do not progress in the cell cycle. When leaving
this milieu the blockade is reversed, e.g. after
159 160 migration of the T-cells to the lymph nodes.
The described scenario may also apply for sarcoi-
dosis where a lymphocyte proliferation can be
observed in sarcoid lymph nodes.
The majority of the findings with regard to
sarcoid T-cell response are characteristic of a T-
cell mediated response to antigen and are highly
suggestive of the presence of a persistent, poorly
degradable antigen or antigens. In 1988 a bias
towards an increased usage of the V8 region of
the T-cell-antigen receptor in sarcoidosis periph-
eral blood and bronchoalveolar lavage T-lympho-
cytes was demonstrated, suggesting that T-cells
accumulate secondary to external selective pres-
sure, rather than in a random polyclonal fashion
or by clonal expansion of one or a few T-cell
clones.2 This observation has been extended
showing restricted usage of T-cell antigen recep-
tor V,-l V,
4 and Cfl-chains
165 in bronch-
oalveolar lavage and lung parenchyma.
However, other technical approaches have
demonstrated an increased clonality in broncho-
alveolar lavage cells without detecting preferred
V-region families, leading to the assumption that
the major source of T-cells is a polyclonal unspe-
cific accumulation accompanied by a clonal
expansion being different in every patient and
contributing about 10% of the T-cells.-9 In
normals an oligoclonality in the V-region usage
of lung T-cell clones compared with blood
clones could not be found. In summary the
sarcoidosis studies revealed a number V- and
Vfl-family selections of the T-cell-antigen receptor
in the detected clones, thus supporting the
hypothesis of an unspecific stimulus. It can be
concluded that the elusive agent or agents elicit-
ing sarcoidosis select T-cell clones in the lung
and other involved organs accompanied by an
unspecific polyclonal T-cell accumulation as
described for normal immune reactions.
71 This
concept of compartmentalization is further sup-
ported by studies of autoimmune and chronic
inflammatory diseases demonstrating a compart-
mentalized accumulation of T-cells with some
restrictions in V-chain gene usage.172-174
The cytokine release by pulmonary lympho-
cytes is an immunopathological co-determinant
of progressing alveolitis. Those patients with high
numbers of activated, IL-2 releasing pulmonary T-
cells have a high risk of developing pulmonary
organ damage requiring corticosteroid therapy.
Patients with low numbers of activated BAL lym-
phocytes or with quiescent cells differ sig-
nificantly with lower percentages of progressing
disease. Thus, parameters of immunopathogen-
esis can be used to gauge the inflammation of
sarcoidosis and to judge prognosis. However, at
present this approach requiring tissue culture is
not applicable in everyday clinical practice.
75
In a recent case report, the interesting course
of a spontaneous improvement of bronchial
176 asthma was described. Bronchial asthma, a
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disease associated with activated T-helper kine expression used in the regulation of inflam-
cell(Th)-2-1ike lymphocytes releasing IL-4 and IL-5 matory reactions.84’88
in the lower respiratory tract in combination with In supernatants of BAL cells from sarcoid
a diminished or even missing IL-2 and IFN, patients, cytokines preferentially produced by
release55’vv’78 came to spontaneous improve- Thl CD4 + cells are frequently found136’153 but
ment when the patient developed sarcoidosis a not the Th2 cytokines IL-4 or IL-10.55’88’8 This
disorder characterized by activated Thl-like lym- indicates that in vivo only active Thl cells are
phocytes expressing Thl cytokines like IL-25 present although Th2 can be elicited from this
and IFN, and the absence of Th2 cytokines cell population in vitro.
82 In the literature con-
like IL-4 and IL-5.
55 This observation supports the siderations about the influence of co-stimulation
concept that similar to bronchial asthma an on the development of Thl and Th2 cells are
imbalance of Thl/Th2 cells might be the under- controversial. There is some evidence that co-sti-
lying immunopathogenetical mechanism which mulation by CD80 decreases disease severity in
can be tested by identifying the cytokines experimental allergic encephalomyelitis by the
released by T-cell clones derived from different activation of Thl cells.89’9 Additionally, it is
body-compartments of patients with sarcoidosis, reported that CD80/CD28 engagement increases
In comparison with other body-compartments the release of IL-2 more than the IL-4 release
using lymphocytes from BAL or pulmonary par- when the T-cell clones used are able to release
enchyma results in a low cloning efficiency.v9 both cytokines.9 The preferential activation of
Specific antigen,
8 which is not available for sar- Thl cells observed in BAL of sarcoid patients
coidosis, or unspecific stimulation
81 are required may thus be a sequela of the exaggerated CD80
to obtain pulmonary T-cell clones. In comparison expression associated with an increased acces-
with blood the analysis of those clones obtained sory function of alveolar macrophages in this
after unspecific stimulation of T-cells from disease,r5
sarcoid patients revealed that in pulmonary par- Another way of down-regulating T-cell activa-
enchyma a shift to Thl cells can be observed, tion is accomplished by anti-inflammatory cyto-
Moreover, clear-cut Thl, Th2, and Th0 cells were kines like IL-10 and TGFI and in the sarcoidosis
found but represented only a minority of the study described above a negative correlation
cells.81-8 Most of the clones expressed the between TGFI release by alveolar cells and their
mRNA and secreted Thl and Th2 cytokines IL-2 release was noted (rs -0.45, p < 0.05,
simultaneously suggesting that they are of inter- Fig. 5).
88 Thus, the down-regulating capabilities
mediate types as recently reviewed by Kelso.
184 of TGFI on activated T-cells found in in vitro
Although only Thl cytokines can be identified in and animal studies76’1- seem to take place in
55 151 BAL fluid and BAL cell supernatants of sar- viva In this regard it is of interest that the activa-
coidosis patients their T-cells from pulmonary tion of T-cells via CD28 is resistant to the down-
parenchyma or BAL are capable of releasing Th2 regulation by TGFI explaining the manifesta-
cytokines. Furthermore, T-cell clones from BAL tion of chronic disease resistant to immunosup-
disclosed in a rather high percentage clear-cut pressive drugs in some patients. In a number of
Th2 cells expressing only IL-4 and It-5.182 These sarcoid patients an increased expression of
findings support the hypothesis that in pulmon- CD80, the ligand of CD28, on alveolar macro-
ary sarcoidosis an imbalance of Thl/Th2 cyto- phages has been demonstrated, indicating the
kines in favour of Thl cytokines maintains the
alveolitis. Th2 cells are present but rendered
quiescent55’82 and in case another stimulus acti-
vates these Th2 cells the sarcoid alveolitis might
so
-0.45
be down-regulated. 0 0.0s
In this context it is of interest that an analysis
on the single cell level of in vitro stimulated BAL 7 0
T-cells from patients with allergic asthma
revealed only a small percentage of cells belong- 0
ing to the Th2 subset and the majority of cells
were releasing IFNT and IL-4 again demonstrating 0
the frequent appearance of intermediate cytokine *
patterns in the human system.
85 Thus, the Thl/
0 , ,
0 ,0’00 ,’00 0’00 00 000 Th0/Th2 cells described in the murine system by
186 187 Mosmann contribute only a small percen- /n/4
tage of the human T-cells and they represent FIG. 5. Correlation of TGFI3 and IL-2 release of alveolar immune
polarised forms of the spectrum of T-cell cyto- cells in pulmonary sarcoidosis, taken from Zissel et aL
88
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possibility of an activation of alveolar T-cells via
this pathway.5’8 Thus, there is strong evidence
that the course of the disease is determined by
the mode of T-cell activation and the balance of
pro- and anti-inflammatory cytokines in the
micromilieu of the lower respiratory tract.
However, there are some findings which indi-
cate that sarcoid T-cells exhibit altered character-
istics of activation resulting in a heightened
resistance to down-regulating mechanisms.
Impaired G-proteins might inhibit adenyl hydro-
lysis leading to cAMP accumulation, thus main-
taining the activated state of the cell.92 In
200
000
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200
A B C D
sarcoidosis and other lung diseases CD95 (Fas) FIG. 6. Soluble IL-2 receptor serum concentration (mean SEM)
at different stages of sarcoidosis. The slL-2R serum levels were is expressed by activated BAL T-cells.193 Normal measured by a commercially available ELISA (DPC/Biermann,
bindin of the riband CDT0 (Fas-D [esuks in Bad Nauheim, Germany)and expressed as U/ml. According to
apoptosis.194 Alterations of the Fas/Fas-L system, clinical criteria the patients were categorized into four groups: A,
active disease without therapy (n 39, 980 4- 74) B, active however, may result in the failure of T-cells to disease under corticosteroid medication (RX)(n 39, 708 -F
undergo apoptosis and an accumulation of acti- 65); C, inactive disease without RX (n 38, 475 -I- 44); D,
vated T-cells at the sites of disease activity.
195 inactive disease without RX (n 51, 434 -I- 34). Statistically
significant differences: p < 0.01, p < 0.05; taken from Other systems mediating apoptosis, as TNF- M011er-Quernheim eta/.201 The normal range (mean -t- 2SD) is
receptors with different intracytoplasmatic signal- indicated by the shaded area (In the mean time the manu-
transducing domains, have been identified and facturer has changed the kit and the upper normal value is now
000 U/ml). this type of receptors are expressed on the
193 196 surface of sarcoid alveolar T-cells. Thus, on
the basis of the present data it cannot be con-
cluded whether the T-cells become activated in serum level reveals an intimate relationship
the course of a normal immune response elicited between this parameter and the clinical activity of
by the unknown agent causing sarcoidosis or if the disease, providing further evidence for the
the sarcoid T-cells induce the disease by failure close linkage between the course of sarcoidosis
of down-regulation after responding to a normal and the activated state of T-cells (Fig. 6).
20o-
antigen.
202,204,205 Moreover, those patients with high slL-
2R serum levels indicating a T-cell activation in
Clinical assessment of T-cell activation: Activated the course of sarcoidosis exhibit a trend to a
T-cells express an IL-2R 55-kD/75-kD heterodimer favourable spontaneous course of the disease
on the cell surface and release a soluble form of with frequent spontaneous regressions and fewer
the 55-kD chain (slL-2R).97’98 slL-2R can be indications for corticoid therapy.
26
found in BAL fluid and serum of sarcoidosis
patients and it is released by activated alveolar
immune cells.99-22 In addition to lymphocytes, Epithelial Cells
macrophages are capable of expressing IL-2R Epithelial cells of the lower respiratory tract,
upon activation2 and it could be demonstrated especially type II pneumocytes, are integrated in
that up to 50% of activated sarcoid alveolar mac- the pulmonary immune response as demon-
rophages exhibit increased numbers of IL-2R.24 strated by their constitutive expression of HLA-
The relative contribution of lymphocytes and DR
207 and their expression of adhesion mole-
macrophages to the alveolar lining fluid slL-2R cules such as CD54, CD51 and CD49d.28’29 Fur-
concentration is not known.201’204 A major con- thermore, TNFz and IL-1, cytokines present in
tribution of these cells to the slL-2R serum level the lower respiratory tract in the course of sar-
cannot be expected because a leakage of the coidosis, are capable of inducing the release of
basal membrane or active transport mechanisms monocyte chemoattractant protein-1 and IL-8 by
allowing a 55-kD protein to leave the alveolar pneumocytes II. In sarcoidosis the activation of
space have not been observed in sarcoidosis.5 these cells is indicated by their production of
In agreement with these findings the slL-2R TGF-,
21 their release of KL-6, a mucin-like
serum concentration was found to be indepen- protein glycoprotein,
2 and their up-regulation
dent of alveolar immune cell activation, indicating of HLA-DR expression.
22
that these cells are not the main contributors to Although the involvement of pneumocytes II in
the exaggerated serum levels of sIL-2R.
2m Never- the immunopathology of interstitial lung diseases
theless, monitoring T-cell activity with slL-2R has been demonstrated, their role in sarcoidosis
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remains to be elucidated. A number of methodo-
logical problems impede their investigation. The
maintenance of pneumocytes II in tissue culture
is difficult23 and they can only be obtained from
patients with interstitial lung diseases when a
diagnostic open lung biopsy, currently a rare
diagnostic procedure, is indicated. The available
methods to isolate pneumocytes II require a
large cell input to obtain sufficient numbers of
pneumocytes II for cell biological experiments.
For future research the preparation techniques
need to be miniaturized to work with thoraco-
scopically obtained lung biopsies or even with
transbronchial biopsies.
In respiratory physiology the most important
product of pneumocytes II is the surface-active
material of the alveolar lining fluid, called surfac-
tant, which reduces surface tension at the alveo-
lar surface, promotes lung expansion on
inspiration and prevents lung collapse on expira-
tion. It is composed of phospholipids and four
apoproteins, named SP-A, B, C, and D.
214 Surfac-
tant as a whole and especially the apoproteins
have pro- and anti-inflammatory properties. In
the presence of surfactant bacteria become
opsonized,
215 macrophages are attracted by che-
motaxis47 and their phagocytosis is stimulated.216
On the other hand surfactant protects the lower
respiratory tract from harmful effects of the
immune system by scavenging radical oxygen
intermediates2v’28 and by inhibiting alveolar
macrophage activation, e.g. the rise of intracel-
lular calcium after activation is blocked by sP-a
44
and the activation of the genes of proin-
flammator cytokines is inhibited on the tran-
scriptional level.29
In interstitial lung diseases including sarcoi-
dosis multiple alterations in the composition of
220 221 surfactant are observed resulting in a loss
of macrophage inhibiting capabilities
4 or even
220 stimulation of these cells. Artificial surfactants
with different amounts of apoproteins and phos-
pholipids are now available as drugs can be
delivered by inhalation.
222 A better understanding
of the immunomodulatory capabilities of surfac-
rant might open new therapeutical approaches
for the treatment of chronic inflammation of the
lower respiratory tract.
Conclusion
Studies of BAL cells, T-cell clones, lymph
nodes and lung parenchyma have advanced our
understanding of the immunopathogenesis of
interstitial lung diseases and, in particular, sarcoid-
osis. New clinical serum parameters allowing to
monitor certain aspects of sarcoid immunopatho-
genesis have been delineated from this know-
ledge. Moreover, in the course of these investiga-
tions it became clear that the pulmonary immune
reaction is compartmentalized. The activated
cells, their mediators, and the corresponding
control mechanisms are confined to the
lung6’63’36’49’53’56’6’69’193 although with
sophisticated methods evidence for immune cell
activation has been obtained from specimens of
the peripheral blood.37’223 Thus, organ-specific
immunoregulatory mechanisms render the lung
into a specialized immunological environment
with a low responsiveness at the site of first
antigen contact.9’159 In spite of the fact that
effective immune stimulation takes place in the
lower respiratory tract only few of the activated
cells undergo mitosis5,5 but leave the
lung16’224 and proliferate in the regional lymph
nodes.6,225
Studies of the pulmonary immune response in
health and disease gave further support for this
concept of compartmentalization. The immu-
noglobulin production of B-lymphocytes of the
lung continues over a relatively long time after
the lung is transplanted and seems to function
independent of the immune system of the
graft.
226 Immunophenotyping of the T-cells on
the alveolar epithelial surface of healthy indi-
viduals revealed that these cells are permanently
activated and exchange only very slowly with the
blood pool5’227 explaining the delayed changes
of the diseased immunophenotypes when the
228 patients are under therapy. Local instillation of
bacteria into the lung leads to neutrophil and
cytokine accumulation in the area of instillation.
If, however, the instillation dose is higher cells
and mediators accumulate in the noninstilled
parts of the lung as well and a systemic cytokine
release is observed229 indicating that the reac-
tions to overwhelming injury cannot be confined
to the lung as it can be seen from the systemic
reaction, e.g. fever and myalgia, in sarcoidosis
and other lung diseases.
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